October 2, 2017

October 2, 2017 – VANCOUVER, BC, BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB) and into the central nervous system for the treatment of neurological diseases and disorders, today announced the appointment of FLG Partner Christopher P. Lowe,  as chief financial officer and board advisor. Lowe will report to Mark Day, Ph.D., president and chief executive officer of biOasis and be responsible for the company’s corporate and financial strategy, including transactions and fundraising.